title: AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
abstract: OBJECTIVE
  To assess potential new prognostic factors and to validate the AIDS Clinical Trials Group (ACTG) for AIDS-related Kaposi's sarcoma (AIDS-KS) staging system in the highly active antiretroviral therapy (HAART) era.
  
  
  METHODS
  We collected epidemiologic, clinical, staging, and survival data from 211 patients with AIDS-KS enrolled in two prospective Italian human immunodeficiency virus (HIV) cohort studies. We included in the analysis all patients with the diagnosis of KS made from January 1996, the time at which HAART became available in Italy.
  
  
  RESULTS
  In the univariate analysis, survival was not influenced by sex, age, level of HIV viremia at KS diagnosis, HAART at KS diagnosis (HAART-naïve v HAART-experienced), or type of HAART combination. Regarding ACTG classification, the 3-year survival rate was 85% for T0 patients and 69% for T1 patients (P =.007), 83% for S0 patients and 63% for S1 patients (P =.003), and 83% for I0 patients and 71% for I1 patients (P =.06). In the multivariate analysis, only the combination of poor tumor stage (T1) and poor systemic disease (S1) risk identified patients with unfavorable prognosis. The 3-year survival rate of patients with T1S1 was 53%, which was significantly lower compared with the 3-year survival rates of patients with T0S0, T1S0, and T0S1, which were 88%, 80%, and 81%, respectively (P =.0001).
  
  
  CONCLUSIONS
  In the era of HAART, a refinement of the original ACTG staging system is needed. CD4 level does not seem to provide prognostic information. Two different risk categories are identified: a good risk (T0S0, T1S0, T0S1) and a poor risk (T1S1).
authors.affiliation: Division of Medical Oncology A, National Cancer Institute, Aviano (PN), Italy.
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Nasti
authors.forename: Renato
authors.initials: R
authors.lastname: Talamini
authors.forename: Andrea
authors.initials: A
authors.lastname: Antinori
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Martellotta
authors.forename: Gaia
authors.initials: G
authors.lastname: Jacchetti
authors.forename: Francesco
authors.initials: F
authors.lastname: Chiodo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ballardini
authors.forename: Laura
authors.initials: L
authors.lastname: Stoppini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
authors.forename: Maurizio
authors.initials: M
authors.lastname: Mena
authors.forename: Marcello
authors.initials: M
authors.lastname: Tavio
authors.forename: Emanuela
authors.initials: E
authors.lastname: Vaccher
authors.forename: Antonella
authors.initials: A
authors.lastname: D'Arminio Monforte
authors.forename: Umberto
authors.initials: U
authors.lastname: Tirelli
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D005260:Female; D015497:HIV-1; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D016019:Survival Analysis